Angiochem Inc
AngioChem is a clinical-stage biotechnology discovering and developing new breakthrough drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases. Their EPiC platform solves the key problem for crossing the blood-brain barrier by developing novel drugs that use a receptor-based approach. These novel Engineered Peptide Compounds (EPiC) have the potential to address significant medical needs, many of which cannot be effectively addressed due to the fundamental physiological challenge the blood-brain barrier presents for therapeutic intervention.
Industries
Nr. of Employees
small (1-50)
Angiochem Inc
Patents
Products
ANG1005
A taxane derivative that crosses the blood-brain barrier to enter cancer cells, targeting LRP-1 receptors highly expressed on the surface of the BBB and various cancer cells.
ANG4043
A peptide-antibody conjugate designed to treat HER2+ breast cancer metastases in the brain by targeting the HER2 receptor and crossing the blood-brain barrier.
ANG2002
A neurotensin derivative conjugated with Angiopep-2 for the management of moderate to severe post-surgical and cancer pain, showing potential as a first-in-class analgesic.
Peptide-Antibody Conjugates
Engineered to cross the blood-brain barrier via receptor-mediated transcytosis, retaining their affinity to the target receptor and in vivo functionality.
Antibody-Drug Conjugates (ADCs)
Biopharmaceuticals composed of an antibody linked to a cytotoxic drug, designed to cross the blood-brain barrier and deliver the drug to tumor cells.
Lysosomal Storage Diseases (LSDs) Treatment
Enzyme derivatives conjugated with Angiopep-2 to increase brain penetration for enzyme replacement therapies, addressing neurological symptoms of LSDs.
ANG1005
A taxane derivative that crosses the blood-brain barrier to enter cancer cells, targeting LRP-1 receptors highly expressed on the surface of the BBB and various cancer cells.
ANG4043
A peptide-antibody conjugate designed to treat HER2+ breast cancer metastases in the brain by targeting the HER2 receptor and crossing the blood-brain barrier.
ANG2002
A neurotensin derivative conjugated with Angiopep-2 for the management of moderate to severe post-surgical and cancer pain, showing potential as a first-in-class analgesic.
Peptide-Antibody Conjugates
Engineered to cross the blood-brain barrier via receptor-mediated transcytosis, retaining their affinity to the target receptor and in vivo functionality.
Antibody-Drug Conjugates (ADCs)
Biopharmaceuticals composed of an antibody linked to a cytotoxic drug, designed to cross the blood-brain barrier and deliver the drug to tumor cells.
Lysosomal Storage Diseases (LSDs) Treatment
Enzyme derivatives conjugated with Angiopep-2 to increase brain penetration for enzyme replacement therapies, addressing neurological symptoms of LSDs.